Beyond DNA damage: Exploring the immunomodulatory effects of cyclophosphamide in multiple myeloma

34Citations
Citations of this article
44Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

The alkylating agent cyclophosphamide has been used in the treatment of multiple myeloma for over 60 years. At low doses, cyclophosphamide also has significant immunomodulatory activity, which can be used to modify the immunosuppressive tumor microenvironment in order to augment responses to existing therapies. Immune-mediated therapies are becoming more widespread in modern approaches to myeloma treatment. In this review, we discuss the effects cyclophosphamide has on the immune system, and how it can be used synergistically with other treatment modalities including the immunomodulatory agents, monoclonal antibodies and cellular therapies.

Cite

CITATION STYLE

APA

Swan, D., Gurney, M., Krawczyk, J., Ryan, A. E., & O’Dwyer, M. (2020). Beyond DNA damage: Exploring the immunomodulatory effects of cyclophosphamide in multiple myeloma. HemaSphere. Wolters Kluwer Health. https://doi.org/10.1097/HS9.0000000000000350

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free